MCID: MLG069
MIFTS: 50

Malignant Hypertension

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Malignant Hypertension

MalaCards integrated aliases for Malignant Hypertension:

Name: Malignant Hypertension 12 15 73
Hypertension, Malignant 44
Hypertension Malignant 55

Classifications:



External Ids:

Disease Ontology 12 DOID:10824
MeSH 44 D006974
NCIt 50 C3118
SNOMED-CT 68 70272006
UMLS 73 C0020540

Summaries for Malignant Hypertension

MalaCards based summary : Malignant Hypertension, also known as hypertension, malignant, is related to malignant hypertensive renal disease and malignant renovascular hypertension. An important gene associated with Malignant Hypertension is REN (Renin), and among its related pathways/superpathways are p70S6K Signaling and Peptide hormone metabolism. The drugs Atorvastatin Calcium and Diazoxide have been mentioned in the context of this disorder. Affiliated tissues include kidney, brain and colon, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 A hypertensive emergency, also known as malignant hypertension, is high blood pressure with potentially... more...

Related Diseases for Malignant Hypertension

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 1
Hypertension, Essential 2 Hypertension, Essential 3
Hypertension, Essential 4 Hypertension, Essential 5
Hypertension, Essential 6 Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Malignant Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 199)
# Related Disease Score Top Affiliating Genes
1 malignant hypertensive renal disease 33.2 EDN1 REN
2 malignant renovascular hypertension 32.0 EDN1 REN
3 malignant essential hypertension 32.0 ACE REN
4 malignant secondary hypertension 31.8 EDN1 REN
5 hypertensive retinopathy 30.4 ACE REN
6 hypertensive encephalopathy 30.3 ACE REN
7 iga glomerulonephritis 30.1 ACE AGTR1 REN
8 nephrosclerosis 29.8 ACE ADAMTS13 AGTR1
9 conn's syndrome 29.7 AGTR1 NPPA REN
10 hypokalemia 29.6 ACE REN
11 end stage renal failure 29.6 ACE AGT AGTR1
12 hypertensive nephropathy 29.5 ACE AGTR1
13 syndrome of inappropriate antidiuretic hormone 29.5 ACE NPPA
14 anuria 29.5 ACE AGT AGTR1 REN
15 vascular disease 29.4 ACE EDN1 REN
16 acute kidney failure 29.3 ADAMTS13 NPPA REN
17 microvascular complications of diabetes 3 29.2 ACE AGT AGTR1
18 arteriosclerosis 29.1 ACE ADM EDN1
19 fibromuscular dysplasia 29.0 ACE AGT AGTR1 REN
20 renal dysplasia 29.0 ACE AGT AGTR1 REN
21 ischemic optic neuropathy 28.8 ACE AGT AGTR1 EDN1
22 renal hypertension 28.7 ACE ADM AGTR1 EDN1 REN
23 diabetes mellitus 28.6 ACE AGT AGTR1 EDN1 REN
24 hypertension, essential 28.4 ACE ADM AGT AGTR1 EDN1 NPPA
25 renovascular hypertension 28.4 ACE ADM AGTR1 EDN1 NPPA REN
26 heart disease 28.4 ACE ADM AGTR1 EDN1 NPPA REN
27 kidney disease 28.3 ACE ADM AGT AGTR1 EDN1 NPPA
28 pre-eclampsia 28.2 ADM AGT AGTR1 EDN1 NPPA REN
29 hemolytic uremic syndrome, atypical 1 11.3
30 hyporeninemic hypoaldosteronism 10.2 ACE REN
31 renal artery obstruction 10.2 ACE REN
32 hypertension, diastolic 10.2 ACE REN
33 orthostatic proteinuria 10.2 ACE REN
34 anterolateral myocardial infarction 10.1 ACE NPPA
35 postural hypotension 10.1 NPPA REN
36 pseudohyperkalemia, familial, 2, due to red cell leak 10.1 ACE REN
37 vasculogenic impotence 10.1 ACE NPPA
38 congenital hepatic fibrosis 10.1 AGTR1 REN
39 pediatric hypertension 10.1 ACE AGT
40 pyelonephritis 10.1
41 encephalopathy 10.1
42 mitral valve insufficiency 10.1 ACE NPPA
43 potter's syndrome 10.1 AGT REN
44 endocrine organ benign neoplasm 10.1 ADM REN
45 glomerulonephritis 10.1
46 carotid artery disease 10.0 ACE REN
47 hyperaldosteronism, familial, type i 10.0 AGT REN
48 pericardial effusion 10.0 NPPA REN
49 hypoaldosteronism 10.0 ACE NPPA REN
50 pure autonomic failure 10.0 ACE NPPA REN

Graphical network of the top 20 diseases related to Malignant Hypertension:



Diseases related to Malignant Hypertension

Symptoms & Phenotypes for Malignant Hypertension

MGI Mouse Phenotypes related to Malignant Hypertension:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.95 ACE ADM AGT AGTR1 EDN1 NPPA
2 homeostasis/metabolism MP:0005376 9.92 ACE ADAMTS13 ADM AGT AGTR1 EDN1
3 hematopoietic system MP:0005397 9.85 ACE ADAMTS13 ADM AGTR1 NPPA REN
4 immune system MP:0005387 9.73 ACE ADAMTS13 ADM AGT AGTR1 REN
5 mortality/aging MP:0010768 9.7 ACE ADAMTS13 ADM AGT AGTR1 EDN1
6 muscle MP:0005369 9.35 ADM AGT EDN1 NPPA REN
7 renal/urinary system MP:0005367 9.17 ACE ADM AGT AGTR1 EDN1 NPPA

Drugs & Therapeutics for Malignant Hypertension

Drugs for Malignant Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Atorvastatin Calcium Phase 3 134523-03-8
2
Diazoxide Approved Phase 2 364-98-7 3019
3
Choline Approved, Nutraceutical Phase 2 62-49-7 305
4 Vasodilator Agents Phase 2
5 Nootropic Agents Phase 2
6 Gastrointestinal Agents Phase 2
7 Antimetabolites Phase 2
8 Lipid Regulating Agents Phase 2
9 Antihypertensive Agents Phase 2
10 Hypolipidemic Agents Phase 2
11
Bevacizumab Approved, Investigational Not Applicable 216974-75-3
12 Cola Not Applicable
13 Angiogenesis Inhibitors Not Applicable
14 Angiogenesis Modulating Agents Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Stenting in Renal Dysfunction Caused by Atherosclerotic Renal Artery Stenosis Completed NCT00150943 Phase 3
2 Diazoxide Choline in Hypertriglyceridemia Completed NCT00696475 Phase 2 Diazoxide choline;Diazoxide choline;Diazoxide choline;Placebo
3 Single Incision Laparoscopy Completed NCT00616616 Not Applicable
4 Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma Completed NCT01810744 Not Applicable
5 A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort Not yet recruiting NCT03755726
6 Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834

Search NIH Clinical Center for Malignant Hypertension

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hypertension, malignant

Genetic Tests for Malignant Hypertension

Anatomical Context for Malignant Hypertension

MalaCards organs/tissues related to Malignant Hypertension:

41
Kidney, Brain, Colon, Liver, Heart, Spinal Cord, Cortex

Publications for Malignant Hypertension

Articles related to Malignant Hypertension:

(show top 50) (show all 798)
# Title Authors Year
1
Severe renal failure and thrombotic microangiopathy induced by malignant hypertension successfully treated with spironolactone. ( 29753419 )
2018
2
Thrombomodulin and Endothelial Dysfunction: A Disease-Modifier Shared between Malignant Hypertension and Atypical Hemolytic Uremic Syndrome. ( 29940557 )
2018
3
A case of malignant hypertension with thrombotic microangiopathy. ( 29512323 )
2018
4
Valsartan Effective for Malignant Hypertension after Aortic Dissection with Renal Artery Involvement. ( 29489021 )
2018
5
20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. ( 30054426 )
2018
6
The case report of capillary leakage syndrome secondary to malignant hypertension. ( 30142799 )
2018
7
Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort. ( 30160657 )
2018
8
Malignant Hypertension in Association with Low Estrogen Dose Oral Contraceptives: Case Report and Review of Literature. ( 30237939 )
2018
9
Fundoscopy & Malignant Hypertension. ( 30395318 )
2018
10
Response of Renal Podocytes to Excessive Hydrostatic Pressure: a Pathophysiologic Cascade in a Malignant Hypertension Model. ( 29224013 )
2017
11
Malignant hypertension as a rare cause of thrombotic microangiopathy. ( 28596204 )
2017
12
Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant Hypertension Registry. ( 28622157 )
2017
13
Orbital haematoma in malignant hypertension. ( 28173968 )
2017
14
Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. ( 28356668 )
2017
15
Malignant Hypertension Revisited-Does This Still Exist? ( 28200072 )
2017
16
Thrombotic microangiopathy due to malignant hypertension complicated with late-onset bleeding after renal biopsy. ( 28679995 )
2017
17
The Etiology of Arteriolar Injury in Malignant Hypertension. ( 29059304 )
2017
18
Response to: The Cause of the Arteriolar Injury in Malignant Hypertension. ( 28985311 )
2017
19
Malignant Hypertension Complicated By Renal Thrombotic Micro Angiopathy: Role Of Adam 13 Mutational Analyses. ( 29076694 )
2017
20
Posterior reversible encephalopathy syndrome in malignant hypertension secondary to focal segmental glomerulosclerosis. ( 27535734 )
2016
21
The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. ( 26778772 )
2016
22
Post-Partum Malignant Hypertension in a Patient with Preeclampsia and Abruptio Placenta. ( 29939706 )
2016
23
An unusual cause of malignant hypertension in young. ( 27728492 )
2016
24
Brain Natriuretic Peptide Counteracting the Renin-angiotensin-aldosterone System in Accelerated Malignant Hypertension. ( 27865304 )
2016
25
CD4(+)CD25(+) T Cells in primary malignant hypertension related kidney injury. ( 27278520 )
2016
26
An ectopic renin-secreting adrenal corticoadenoma in a child with malignant hypertension. ( 26997629 )
2016
27
Malignant hypertension: new aspects of an old clinical entity. ( 26658350 )
2016
28
[OP.LB.02.05] A PATIENT WITH MALIGNANT HYPERTENSION SUCCESSFULLY TREATED WITH ECULIZUMAB AND BOSENTAN - SUGGESTIONS OF SIGNIFICANT INTERACTIONS OF COMPLEMENT AND THE ENDOTHELIN SYSTEM IN BLOOD PRESSURE CONTROL. ( 27508801 )
2016
29
Fenofibrate Attenuates Malignant Hypertension by Suppression of the Renin-angiotensin System: A Study in Cyp1a1-Ren-2 Transgenic Rats. ( 27916218 )
2016
30
Idiopathic midaortic syndrome with malignant hypertension in 3-year-old boy. ( 28018454 )
2016
31
Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. ( 26833491 )
2016
32
A global amnesia associated with the specific variant of posterior reversible encephalopathy syndrome (PRES) that developed due to severe preeclampsia and malignant hypertension. ( 27099774 )
2016
33
Malignant Hypertension with Thrombotic Microangiopathy. ( 27523008 )
2016
34
IMAGES IN CLINICAL MEDICINE. Reversible Loss of Vision in Malignant Hypertension. ( 27050208 )
2016
35
SPONTANEOUS BILATERAL HEMORRHAGIC CHOROIDAL DETACHMENTS ASSOCIATED WITH MALIGNANT HYPERTENSION. ( 27177073 )
2016
36
Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. ( 27428043 )
2016
37
Takayasu arteritis presenting with malignant hypertension; a rare manifestation of a rare disease: a case report and review of the literature. ( 27216226 )
2016
38
A case report of malignant hypertension in a young woman. ( 27389397 )
2016
39
Malignant hypertension-associated thrombotic microangiopathy following cocaine use. ( 26787585 )
2016
40
First reported case of khat cardiomyopathy and malignant hypertension in Australia. ( 27981767 )
2016
41
Basal transethmoidal encephalocele and malignant hypertension in a parturient with a seizure disorder. A case report. ( 25745752 )
2015
42
Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis. ( 25611832 )
2015
43
Malignant Hypertension and Thrombotic Thrombocytopenic Purpura: False Friends. ( 26083445 )
2015
44
Candida-associated pseudo-aneurysm of the transplant renal artery presenting as malignant hypertension and managed successfully without nephrectomy. ( 26354578 )
2015
45
Does Anticomplement Therapy Have a Role in the Management of Malignant Hypertension? ( 26359936 )
2015
46
Severe visual loss caused by unrecognized malignant hypertension in a 15-year-old girl. ( 25868960 )
2015
47
Increasing trend in admissions for malignant hypertension and hypertensive encephalopathy in the United States. ( 25801877 )
2015
48
Malignant Hypertension: Clinical Manifestations of 7 Cases. ( 25902134 )
2015
49
Bilateral exudative retinal detachment with choroidopathy in malignant hypertension. ( 27132968 )
2015
50
Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. ( 26137201 )
2015

Variations for Malignant Hypertension

Expression for Malignant Hypertension

Search GEO for disease gene expression data for Malignant Hypertension.

Pathways for Malignant Hypertension

GO Terms for Malignant Hypertension

Cellular components related to Malignant Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ACE ADAMTS13 ADM AGT EDN1 NPPA
2 extracellular space GO:0005615 9.17 ACE ADAMTS13 ADM AGT EDN1 NPPA

Biological processes related to Malignant Hypertension according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 ADM AGT EDN1 NPPA
2 cell-cell signaling GO:0007267 9.84 ADM AGT EDN1
3 response to hypoxia GO:0001666 9.82 ADM EDN1 NPPA
4 response to lipopolysaccharide GO:0032496 9.82 ADM EDN1 REN
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.73 ADM AGT AGTR1 EDN1
6 female pregnancy GO:0007565 9.71 ADM AGT NPPA
7 cellular response to drug GO:0035690 9.69 EDN1 REN
8 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.69 AGT AGTR1
9 positive regulation of endothelial cell migration GO:0010595 9.69 AGT EDN1
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.68 AGT EDN1
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.68 AGT EDN1
12 regulation of cardiac conduction GO:1903779 9.68 AGT NPPA
13 positive regulation of protein tyrosine kinase activity GO:0061098 9.68 ACE AGT
14 blood vessel remodeling GO:0001974 9.67 ACE AGT
15 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.67 AGTR1 EDN1
16 kidney development GO:0001822 9.67 ACE AGT AGTR1 REN
17 positive regulation of reactive oxygen species metabolic process GO:2000379 9.66 AGT AGTR1
18 positive regulation of cardiac muscle hypertrophy GO:0010613 9.66 AGT EDN1
19 positive regulation of blood vessel diameter GO:0097755 9.65 ADM AGT
20 positive regulation of blood pressure GO:0045777 9.65 ACE AGT
21 positive regulation of cellular protein metabolic process GO:0032270 9.64 AGT AGTR1
22 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.63 AGT AGTR1
23 vasoconstriction GO:0042310 9.63 AGT EDN1
24 cell growth involved in cardiac muscle cell development GO:0061049 9.62 AGT NPPA
25 response to muscle stretch GO:0035994 9.62 EDN1 NPPA
26 amyloid-beta metabolic process GO:0050435 9.61 ACE REN
27 low-density lipoprotein particle remodeling GO:0034374 9.61 AGT AGTR1
28 peptide catabolic process GO:0043171 9.6 ACE ADAMTS13
29 positive regulation of renal sodium excretion GO:0035815 9.59 AGT EDN1
30 regulation of blood vessel diameter GO:0097746 9.58 ACE AGTR1
31 positive regulation of heart rate GO:0010460 9.58 ADM EDN1 NPPA
32 angiotensin maturation GO:0002003 9.57 ACE REN
33 artery smooth muscle contraction GO:0014824 9.56 AGT EDN1
34 positive regulation of cholesterol esterification GO:0010873 9.55 AGT AGTR1
35 positive regulation of NAD(P)H oxidase activity GO:0033864 9.52 AGT AGTR1
36 regulation of renal sodium excretion GO:0035813 9.51 AGT AGTR1
37 regulation of blood vessel size GO:0050880 9.5 AGT EDN1 NPPA
38 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.49 AGT AGTR1
39 regulation of blood volume by renin-angiotensin GO:0002016 9.48 AGT REN
40 regulation of renal output by angiotensin GO:0002019 9.46 ACE AGT
41 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.43 ACE AGT AGTR1
42 renin-angiotensin regulation of aldosterone production GO:0002018 9.33 AGT AGTR1 REN
43 regulation of vasoconstriction GO:0019229 9.26 ACE AGT AGTR1 EDN1
44 regulation of blood pressure GO:0008217 9.02 ACE AGT EDN1 NPPA REN

Molecular functions related to Malignant Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.46 ADM EDN1 NPPA REN
2 bradykinin receptor binding GO:0031711 8.96 ACE AGTR1
3 hormone activity GO:0005179 8.92 ADM AGT EDN1 NPPA

Sources for Malignant Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....